221 related articles for article (PubMed ID: 24372914)
1. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
Stott SRW; Barker RA
Eur J Neurosci; 2014 Mar; 39(6):1042-1056. PubMed ID: 24372914
[TBL] [Abstract][Full Text] [Related]
2. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
3. Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson's Disease in C57BL/6 Mice.
Deng I; Corrigan F; Garg S; Zhou XF; Bobrovskaya L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299000
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
Boshoff EL; Fletcher EJR; Duty S
Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
6. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Sleeman IJ; Boshoff EL; Duty S
Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
[TBL] [Abstract][Full Text] [Related]
8. A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: a stereological study.
Healy-Stoffel M; Ahmad SO; Stanford JA; Levant B
J Neurosci Methods; 2012 Sep; 210(2):187-94. PubMed ID: 22850559
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
10. ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.
Salvatore MF
J Neurochem; 2014 May; 129(3):548-58. PubMed ID: 24410633
[TBL] [Abstract][Full Text] [Related]
11. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
[TBL] [Abstract][Full Text] [Related]
14. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
Stayte S; Rentsch P; Li KM; Vissel B
PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
[TBL] [Abstract][Full Text] [Related]
15. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease.
Yin LH; Shen H; Diaz-Ruiz O; Bäckman CM; Bae E; Yu SJ; Wang Y
BMC Neurosci; 2012 Oct; 13():120. PubMed ID: 23040108
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
17. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
[TBL] [Abstract][Full Text] [Related]
18. Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse.
Becker B; Demirbas M; Johann S; Zendedel A; Beyer C; Clusmann H; Haas SJ; Wree A; Tan SKH; Kipp M
Mol Neurobiol; 2018 May; 55(5):4240-4252. PubMed ID: 28616718
[TBL] [Abstract][Full Text] [Related]
19. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
Kim HD; Jeong KH; Jung UJ; Kim SR
J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of RET and GDNF family receptor, GFR-α1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling.
Kasanga EA; Han Y; Navarrete W; McManus R; Shifflet MK; Parry C; Barahona A; Manfredsson FP; Nejtek VA; Richardson JR; Salvatore MF
Exp Neurol; 2023 Aug; 366():114435. PubMed ID: 37178997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
